ASP Reporting Could Prompt Changes In Manufacturer Contracts With PBMs
The Centers for Medicare & Medicaid Services' reporting requirements for average sales price could necessitate changes to contracts between manufacturers and purchasers, Schering-Plough Legal Director David Ralston suggested Aug. 3 during a Healthcare Marketplace audioconference on sales price reporting
You may also be interested in...
The Centers for Medicare & Medicaid Services' position that bona fide service fees paid by manufacturers to wholesalers are exempt from average sales price calculations may not resolve problems with the fee-for-service distribution model, Sidley Austin Brown & Wood attorney William Sarraille said
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials